CompletedNCT02360319
Long-Acting Injectable Antipsychotic or Clinician’s Choice Early in Schizophrenia
About this title
Read the official source — NCT02360319Medication studyAges 18–35United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 35 years. Other eligibility criteria applied.
- Listed locations
- Tucson and 38 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: December 11, 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 489
- Sponsor
- Vanguard Research Group
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 35 Years
- Official registry ID
- NCT02360319
- Official title
Show the full official title
A Cluster Randomized, Multi-center, Parallel-group, Rater-blind Study Comparing Treatment With Aripiprazole Once Monthly and Treatment as Usual on Effectiveness in First Episode and Early Phase Illness in Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tucson · Granada Hills · Palo Alto
35 more locations
- Fort Lauderdale
- Gainesville
- Jacksonville
- Leesburg
- St. Petersburg
- Tallahassee
- West Palm Beach
- Atlanta
- Augusta
- Chicago
- Granite City
- Iowa City
- Fall River
- Worcester
- Ann Arbor
- East Lansing
- Grand Rapids
- Kalamazoo
- Mount Pleasant
- Muskegon
- St Louis
- Omaha
- Manchester
- Nashua
- Paramus
- Durham
- Cincinnati
- Wooster
- Eugene
- Huntingdon
- Beaumont
- Houston
- Longview
- San Antonio
- Salt Lake City
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Vanguard Research Group.
Did this study involve medication?
Yes. The study involved medication, including Any FDA approved antipsychotic agent and aripiprazole long acting injectable formulation.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 35 years. Other eligibility criteria applied.
